Future related costs for Myocardial Infarction survivors

This project looked at survivors of myocardial infarction (MI) developing other conditions in future. NICE guidance currently states that costs unrelated to the condition or technology of interest should be excluded from cost-effectiveness analysis.  

This is controversial and could have substantial impact on the results and conclusions of analyses, particularly where there is an effect on mortality. This project describes different types of cost and whether/how these might be included in cost-effectiveness analysis. 

Read about our research in more detail by accessing our publication on